Teva, AstraZeneca settle patent dispute over multimillion-dollar drug

Teva Pharmaceuticals USA Inc. said Thursday it has settled patent litigation with AstraZeneca Pharmaceuticals and Amylin Pharmaceuticals that involved the prescription medicine Byetta. Byetta is an injectable drug used to improve blood sugar control in adults with type 2 diabetes. The drug generated revenues of $316 million for AstraZeneca in 2015. Under the terms of the settlement, AstraZeneca (NYSE: AZN) granted a license to Teva (NYSE: TEVA) to manufacture and commercialize the generic version…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news